Michael A. Beazely, Ph.D. - Publications

2004 Purdue University, West Lafayette, IN, United States 

31/40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Bradley RM, Mardian EB, Marvyn PM, Vasefi MS, Beazely MA, Mielke JG, Duncan RE. Data on acylglycerophosphate acyltransferase 4 (AGPAT4) during murine embryogenesis and in embryo-derived cultured primary neurons and glia. Data in Brief. 6: 28-32. PMID 26759825 DOI: 10.1016/J.Dib.2015.11.033  1
2015 Kruk JS, Vasefi MS, Gondora N, Ahmed N, Heikkila JJ, Beazely MA. Fluoxetine-induced transactivation of the platelet-derived growth factor type β receptor reveals a novel heterologous desensitization process. Molecular and Cellular Neurosciences. 65: 45-51. PMID 25702926 DOI: 10.1016/J.Mcn.2015.02.013  1
2015 Tin G, Mohamed T, Gondora N, Beazely MA, Rao PPN. Tricyclic phenothiazine and phenoselenazine derivatives as potential multi-targeting agents to treat Alzheimer's disease Medchemcomm. 6: 1930-1941. DOI: 10.1039/C5Md00274E  1
2014 Samarajeewa A, Goldemann L, Vasefi MS, Ahmed N, Gondora N, Khanderia C, Mielke JG, Beazely MA. 5-HT7 receptor activation promotes an increase in TrkB receptor expression and phosphorylation. Frontiers in Behavioral Neuroscience. 8: 391. PMID 25426041 DOI: 10.3389/Fnbeh.2014.00391  1
2014 Alqawlaq S, Sivak JM, Huzil JT, Ivanova MV, Flanagan JG, Beazely MA, Foldvari M. Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 1637-47. PMID 24905400 DOI: 10.1016/J.Nano.2014.05.010  1
2014 Kruk JS, Kouchmeshky A, Grimberg N, Rezkella M, Beazely MA. Transactivation of receptor tyrosine kinases by dopamine receptors Dopamine Receptor Technologies. 211-227. DOI: 10.1007/978-1-4939-2196-6_12  1
2013 Kruk JS, Vasefi MS, Heikkila JJ, Beazely MA. Reactive oxygen species are required for 5-HT-induced transactivation of neuronal platelet-derived growth factor and TrkB receptors, but not for ERK1/2 activation. Plos One. 8: e77027. PMID 24086766 DOI: 10.1371/Journal.Pone.0077027  1
2013 Vasefi MS, Yang K, Li J, Kruk JS, Heikkila JJ, Jackson MF, MacDonald JF, Beazely MA. Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. Molecular Brain. 6: 24. PMID 23672716 DOI: 10.1186/1756-6606-6-24  1
2013 Vasefi MS, Kruk JS, Heikkila JJ, Beazely MA. 5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGFβ receptor dependent. Journal of Neurochemistry. 125: 26-36. PMID 23336565 DOI: 10.1111/Jnc.12157  1
2013 Kruk JS, Vasefi MS, Liu H, Heikkila JJ, Beazely MA. 5-HT(1A) receptors transactivate the platelet-derived growth factor receptor type beta in neuronal cells. Cellular Signalling. 25: 133-43. PMID 23006663 DOI: 10.1016/J.Cellsig.2012.09.021  1
2012 Mohamed T, Yeung JC, Vasefi MS, Beazely MA, Rao PP. Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. Bioorganic & Medicinal Chemistry Letters. 22: 4707-12. PMID 22704921 DOI: 10.1016/J.Bmcl.2012.05.077  1
2012 Vasefi MS, Kruk JS, Liu H, Heikkila JJ, Beazely MA. Activation of 5-HT7 receptors increases neuronal platelet-derived growth factor β receptor expression. Neuroscience Letters. 511: 65-9. PMID 22285262 DOI: 10.1016/J.Neulet.2012.01.016  1
2010 Peng F, Yao H, Bai X, Zhu X, Reiner BC, Beazely M, Funa K, Xiong H, Buch S. Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. The Journal of Biological Chemistry. 285: 21615-24. PMID 20452974 DOI: 10.1074/Jbc.M110.107003  1
2010 Bartos JA, Ulrich JD, Li H, Beazely MA, Chen Y, Macdonald JF, Hell JW. Postsynaptic clustering and activation of Pyk2 by PSD-95. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 449-63. PMID 20071509 DOI: 10.1523/Jneurosci.4992-08.2010  1
2009 Yang K, Trepanier CH, Li H, Beazely MA, Lerner EA, Jackson MF, MacDonald JF. Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission. Hippocampus. 19: 779-89. PMID 19173226 DOI: 10.1002/Hipo.20559  1
2009 Beazely MA, Lim A, Li H, Trepanier C, Chen X, Sidhu B, Macdonald JF. Platelet-derived growth factor selectively inhibits NR2B-containing N-methyl-D-aspartate receptors in CA1 hippocampal neurons. The Journal of Biological Chemistry. 284: 8054-63. PMID 19106110 DOI: 10.1074/Jbc.M805384200  1
2008 Beazely MA, Weerapura M, MacDonald JF. Abelson tyrosine kinase links PDGFbeta receptor activation to cytoskeletal regulation of NMDA receptors in CA1 hippocampal neurons. Molecular Brain. 1: 20. PMID 19077273 DOI: 10.1186/1756-6606-1-20  1
2008 Thompson RJ, Jackson MF, Olah ME, Rungta RL, Hines DJ, Beazely MA, MacDonald JF, MacVicar BA. Activation of pannexin-1 hemichannels augments aberrant bursting in the hippocampus. Science (New York, N.Y.). 322: 1555-9. PMID 19056988 DOI: 10.1126/Science.1165209  1
2007 MacDonald JF, Jackson MF, Beazely MA. G protein-coupled receptors control NMDARs and metaplasticity in the hippocampus. Biochimica Et Biophysica Acta. 1768: 941-51. PMID 17261268 DOI: 10.1016/J.Bbamem.2006.12.006  1
2006 MacDonald JF, Jackson MF, Beazely MA. Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. Critical Reviews in Neurobiology. 18: 71-84. PMID 17725510 DOI: 10.1615/Critrevneurobiol.V18.I1-2.80  1
2006 Beazely MA, Tong A, Wei WL, Van Tol H, Sidhu B, MacDonald JF. D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent. Journal of Neurochemistry. 98: 1657-63. PMID 16879713 DOI: 10.1111/J.1471-4159.2006.04064.X  1
2006 Beazely MA, Watts VJ. Regulatory properties of adenylate cyclases type 5 and 6: A progress report. European Journal of Pharmacology. 535: 1-12. PMID 16527269 DOI: 10.1016/J.Ejphar.2006.01.054  1
2005 Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, Roder JC, Orser BA, MacDonald JF. Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 11374-84. PMID 16339032 DOI: 10.1523/Jneurosci.3871-05.2005  1
2005 Beazely MA, Watts VJ. Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation. Biochemical Pharmacology. 70: 113-20. PMID 15885660 DOI: 10.1016/J.Bcp.2005.04.007  1
2005 Beazely MA, Watts VJ. Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6. Cellular Signalling. 17: 647-53. PMID 15683739 DOI: 10.1016/J.Cellsig.2004.10.003  1
2005 Beazely MA, Alan JK, Watts VJ. Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Molecular Pharmacology. 67: 250-9. PMID 15470083 DOI: 10.1124/Mol.104.001370  1
2004 Johnston CA, Beazely MA, Bilodeau ML, Andrisani O, Watts VJ. Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line. Journal of Neurochemistry. 88: 1497-508. PMID 15009651 DOI: 10.1046/J.1471-4159.2004.02285.X  1
2002 Johnston CA, Beazely MA, Vancura AF, Wang JK, Watts VJ. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells. Journal of Neurochemistry. 82: 1087-96. PMID 12358756 DOI: 10.1046/J.1471-4159.2002.01033.X  1
2000 Dimmock JR, Kumar P, Nazarali AJ, Motaganahalli NL, Kowalchuk TP, Beazely MA, Wilson Quail J, Oloo EO, Allen TM, Szydlowski J, DeClercq E, Balzarini J. Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds. European Journal of Medicinal Chemistry. 35: 967-77. PMID 11137225 DOI: 10.1016/S0223-5234(00)01173-9  1
1999 Dimmock JR, Elias DW, Beazely MA, Kandepu NM. Bioactivities of chalcones. Current Medicinal Chemistry. 6: 1125-49. PMID 10519918  1
1999 Dimmock JR, Semple HA, John S, Beazely MA, Abrams GD. Isolation and identification of the major urinary metabolite of 4-(4-fluorophenoxy)benzaldehyde semicarbazone after oral dosing to rats. Die Pharmazie. 54: 260-2. PMID 10234738  1
Low-probability matches
2021 Gondora N, Pople CB, Tandon G, Robinson M, Solomon E, Beazely MA, Mielke JG. Chronic early-life social isolation affects NMDA and TrkB receptor expression in a sex-specific manner. Neuroscience Letters. 136016. PMID 34111511 DOI: 10.1016/j.neulet.2021.136016  0.01
2021 Gondora N, Sanyal C, Carter C, Nethercott A, Sproule B, Turcotte D, Halpape K, Bishop LD, Nissen L, Beazely MA, Kwong M, Versteeg S, Chang F. The role of pharmacists in opioid stewardship: Protocol. Research in Social & Administrative Pharmacy : Rsap. 17: 993-996. PMID 33773640 DOI: 10.1016/J.Sapharm.2020.06.027  0.01
2021 Cid A, Daskalakis G, Grindrod K, Beazely MA. What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review. Pharmacy (Basel, Switzerland). 9. PMID 33540676 DOI: 10.3390/pharmacy9010030  0.01
2020 So R, Al Hamarneh Y, Barnes M, Beazely MA, Boivin M, Laroche J, Patel H, Sihota A, Smith T, Tsuyuki RT. The status of naloxone in community pharmacies across Canada. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 153: 352-356. PMID 33282025 DOI: 10.1177/1715163520958435  0.01
2020 Tsuyuki RT, Arora V, Barnes M, Beazely MA, Boivin M, Christofides A, Patel H, Laroche J, Sihota A, So R. Canadian national consensus guidelines for naloxone prescribing by pharmacists. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 153: 347-351. PMID 33282024 DOI: 10.1177/1715163520949973  0.01
2019 Lai D, Pham AT, Nekkar Rao PP, Beazely MA. The effects of heat and freeze-thaw cycling on naloxone stability. Harm Reduction Journal. 16: 17. PMID 30813917 DOI: 10.1186/S12954-019-0288-4  0.01
2018 Liu H, Saffi GT, Vasefi MS, Choi Y, Kruk JS, Ahmed N, Gondora N, Mielke J, Leonenko Z, Beazely MA. Amyloid-β inhibits PDGFβ receptor activation and prevents PDGF-BB-induced neuroprotection. Current Alzheimer Research. PMID 29332578 DOI: 10.2174/1567205015666180110110321  0.01
2016 Grindrod K, Beazely M. Fitting naloxone into community pharmacy practice. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 149: 329-331. PMID 27829855 DOI: 10.1177/1715163516671968  0.01
2016 Osman W, Mohamed T, Sit VM, Vasefi MS, Beazely MA, Rao PP. Structure-Activity Relationship Studies of Benzyl, Phenethyl and Pyridyl Substituted Tetrahydroacridin-9-amines as Multi-targeting Agents to treat Alzheimer's Disease. Chemical Biology & Drug Design. PMID 27282589 DOI: 10.1111/Cbdd.12800  0.01
Hide low-probability matches.